Toronto · Independent Shariah screening · Screened October 1, 2026

TSX Shariah screener · October 2026

Medicenna Therapeutics Corp.

MDNA · TSX · Healthcare

FAIL

Is Medicenna Therapeutics Corp. (MDNA) Halal?

Debt ÷ market cap 0% / 33%

Medicenna Therapeutics Corp. · TSX: MDNA · Healthcare

Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.

The short answer

No — Medicenna Therapeutics (MDNA) fails this Shariah stock screen. Its engineered cytokine immunotherapy business (bizaxofusp/MDNA55, Superkines) is permissible and it carries no debt, but its separately disclosed 'Finance income' line — which the company says consists only of interest earned on excess cash, cash equivalents, and marketable securities — is the company's only income: it is pre-revenue with nil sales, far above the 5% non-compliant income limit. (The Q1 FY2027 release confirms the line's existence, citing a $0.2M decrease in finance income; the exact Q1 absolute figure was not retrieved — the FAIL logic does not depend on it.) The Nasdaq delisting was October 2023 only; the TSX listing continues. No Zoya, Musaffa, or ShariaPortfolio rating was found for this ticker — honestly reported as absent, not invented.

Gate 1 — Business activity: PASS

Medicenna Therapeutics Corp. (TSX:MDNA) is a pre-revenue biotech developing engineered cytokine immunotherapy (bizaxofusp/MDNA55, Superkines) for cancer and autoimmune disease; its interim financial statements describe it as being in the development stage with no revenues from product candidates. The Nasdaq delisting was October 2023 only — the TSX listing (plus OTCQX) continues. No alcohol, pork, gambling, conventional interest-based lending, tobacco, cannabis, weapons, or adult-entertainment lines were disclosed. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Debt is about C$0 — debt ÷ market cap is about 0%, well under the ~33% ceiling. Cash of C$5.7M (June 30, 2026) is about 18.2% of the ~C$31.4M market cap (C$0.41, September 23, 2026). Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: FAIL

The company discloses a separate 'Finance income' line that it says consists only of interest earned on excess cash, cash equivalents, and marketable securities — while it is pre-revenue with nil sales. The Q1 FY2027 release (August 14, 2026) confirms the line, citing a $0.2M decrease in finance income as driving a higher net loss. Interest is effectively 100% of the company's income, far above the 5% non-compliant income limit. Gate 3 fails. Facts only.

BDS screen

Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.

No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).

Moral screen

Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.

Israeli military business
No findings published.
US military business
No findings published.
Weapons manufacturing & arms trade
No findings published.

Key figures used

Halal alternatives in this sector

MDNA did not pass the screen. These companies in the same sector passed:

Frequently asked questions

Is Medicenna Therapeutics (MDNA) halal?

No. Medicenna Therapeutics fails this Shariah stock screen. Its engineered cytokine immunotherapy business (bizaxofusp/MDNA55, Superkines) is permissible and it carries no debt, but its separately disclosed 'Finance income' line — which the company says consists only of interest earned on excess cash, cash equivalents, and marketable securities — is the company's only income: it is pre-revenue with nil sales, far above the 5% limit for non-compliant income. The Nasdaq delisting was October 2023 only; the TSX listing continues. This is a factual screen, not a religious ruling — consult a qualified scholar for personal guidance.

What is Medicenna Therapeutics' debt-to-market-cap ratio?

About 0%. Debt is essentially nil, well under the ~33% ceiling. Cash of C$5.7M (June 30, 2026) is about 18.2% of the ~C$31.4M market cap (C$0.41, September 23, 2026).

What does Medicenna Therapeutics do?

Medicenna Therapeutics Corp. (TSX:MDNA) is a pre-revenue biotech developing engineered cytokine immunotherapy (bizaxofusp/MDNA55, Superkines) for cancer and autoimmune disease; its interim financial statements describe it as being in the development stage with no revenues from product candidates.

How much finance income does Medicenna Therapeutics earn relative to revenue?

The company discloses a separate 'Finance income' line that it says consists only of interest earned on excess cash, cash equivalents, and marketable securities — while it is pre-revenue with nil sales. The Q1 FY2027 release (August 14, 2026) confirms the line, citing a $0.2M decrease in finance income. Interest is effectively 100% of the company's income, far above the 5% ceiling.

Where can I find more healthcare stock screeners?

See halal-stock-verdicts.html for the full list of stock screeners, including the other healthcare-sector entries.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.